Open AccessFeasibility and efficacy of a mass switch from ranibizumab (Lucentis) to bevacizumab (Avastin) for treatment of neovascular age-related macular degeneration
Author(s) -
Michael Andreoli,
Michael Pinnolis,
Troy Kieser,
Jennifer K. Sun,
Christopher M. Andreoli
Publication year - 2015
Publication title -
digital journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.223
H-Index - 7
ISSN - 1542-8958
DOI - 10.5693/djo.01.2015.04.002
Subject(s) - macular degeneration , ranibizumab , bevacizumab , medicine , ophthalmology , chemotherapy
To assess the feasibility and potential obstacles of a departmental switch from ranibizumab (Lucentis, Genentech, South San Francisco, CA) to bevacizumab (Avastin, Genentech) for the treatment of neovascular age-related macular degeneration (AMD).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom